Northwire Canada EditionFriday, November 6, 2026
Sign inSubscribe
Northwire
⌕
Gold 4,113.50 +1.0% Silver 52.38 +0.2% Copper 6.21 −3.4% Oil 90.52 +2.7% Palladium 1,034.00 +3.1% GRZ 5.25 −8.7% TNGD 5.20 +2.0% IMG 24.46 −0.1% III 6.05 −2.6% SCMI 0.900 −5.3% TSK 0.810 −1.2% MEK 0.040 +0.0% GAU 2.99 +2.0% SVM 11.69 −3.5% NGEX 20.70 −4.6% WPM 185.96 +1.2% ETG 2.58 −7.9% CG 29.87 −0.2% EMO 0.190 −2.6% TUF 0.660 −5.7% APMI 0.095 −13.6% Gold 4,113.50 +1.0% Silver 52.38 +0.2% Copper 6.21 −3.4% Oil 90.52 +2.7% Palladium 1,034.00 +3.1% GRZ 5.25 −8.7% TNGD 5.20 +2.0% IMG 24.46 −0.1% III 6.05 −2.6% SCMI 0.900 −5.3% TSK 0.810 −1.2% MEK 0.040 +0.0% GAU 2.99 +2.0% SVM 11.69 −3.5% NGEX 20.70 −4.6% WPM 185.96 +1.2% ETG 2.58 −7.9% CG 29.87 −0.2% EMO 0.190 −2.6% TUF 0.660 −5.7% APMI 0.095 −13.6%
Financings

Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements

By The Northwire Desk — AI Analysis Mar 05, 2026 · 20:06 RKV · 0.15 Rakovina Therapeutics Inc.
RKV · Price

Executive Summary

  • Rakovina Therapeutics closed a non‑brokered private placement of convertible debenture units, raising $1,000,000 in gross proceeds.
  • The company settled its existing 12 % unsecured convertible debentures (total outstanding $1,587,130.59) by issuing approximately 3,265,585 settlement shares and new replacement debentures plus warrants valued at $1,195,259.99.
  • Closing of the debt‑settlement transactions is expected around March 9, 2026, subject to TSX Venture Exchange approval.

Key Details

  • Private Placement Terms
  • Price: $50,000 per Debenture Unit.
  • Each unit comprised of one $50,000 unsecured convertible debenture and 100,000 warrants.
  • Warrants exercisable at $0.20 per share until Jan 28 2029 (subject to adjustments).

  • New debentures bear 12 % interest, payable semi‑annually in cash or common shares, maturing Jan 28 2029 with conversion option at $0.20 per share.

  • Use of Proceeds

  • Near‑term working capital for ongoing corporate activities and strategic initiatives; longer‑term financing options remain under evaluation.

  • Debt Settlement Structure

  • Total settled amount: $1,587,130.59 (principal $1,454,000 + accrued interest $133,130.59).
  • Settlement option A: Holders receive 3,265,585 settlement shares at a deemed price of $0.12 per share for $391,870.60 of debt.

  • Settlement option B: Remaining holders receive Replacement Debentures (principal $1,095,000) plus 2,390,519 warrants, covering the balance of $1,195,259.99.

  • Replacement Debenture & Warrant Terms

  • Identical to the new debentures and warrants issued in the private placement (12 % interest, $0.20 exercise price, same maturity).

  • Regulatory Conditions

  • All issuances subject to final approval by the TSX Venture Exchange (TSXV).
  • Securities will be under a statutory hold period of four months and one day from issuance per Canadian securities law.

Notable Quotes

(No executive quotes were included in the release.)

Read the original news release →

More from Rakovina Therapeutics Inc.

Jun 01, 2026 · 17:00

Rakovina Cuts Costs and Restructures Debt, But Pre-Revenue Burn Rate Demands Immediate Capital Infusion

Earnings Apr 30, 2026 · 17:10

Rakovina Therapeutics Confirms Accelerating Burn Rate and Critical Cash Position Despite Financing

Earnings Apr 22, 2026 · 04:00

AI-Driven Oncology Pipeline Validates Preclinical Efficacy

Other Mar 23, 2026 · 04:00

Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 - World's Premier Cancer Research Forum

Other Mar 12, 2026 · 15:28

Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement

Financings Mar 05, 2026 · 20:50

Rakovina closes $1-million debenture unit financing

Financings